In this interview with Francesco Lo-coco we discussed a randomized clinical trial conducted with the drug Trisenox as well as, the genetic characterization, monitoring and treatment of hematologic tumors, particularly acute promyelocytic leukemia.
This article summarizes the outcome of a randomized phase III clinical trial investigating the effect of FLT3 inhibitors to improve FTL3-mutated acute myeloid leukemia
In this interview from the International Journal of Hematologic Oncology Donna E Reece from the Princess Margaret Hospital/University of Toronto (Canada) speaks about the management of multiple myeloma in Canada.
This case report details the successful management of a 99-year old lymphoma patient.
In this review article from the International Journal of Hematologic Oncology read about the clinical benefits of utilizing tyrosine kinase inhibitors in combination with chemotherapy regimes for Philadelphia chromosome-positive acute lymphoblastic leukemia patients.
This review article from the International Journal of Hematologic Oncology offers a detailed overview of the role of B-cell receptor signaling pathways in B-cell malignancies, discussing how a greater understanding of such pathways has led to the discovery of numerous drug targets.
This review presents an update on recent progress in characterizing recurrent genetic abnormalities in AML, focusing on prognostic significance and therapeutic implications.
Learn further about the mechanism of action of currently available and future immunotherapy strategies for multiple myeloma, while also exploring ways in which treatment may be more specifically directed in the future.
Read more on the compelling challenge of treating elderly patients with CLL in this excellent review article from our partner journal, the International Journal of Hematologic Oncology.
This review discusses the role of cytotoxic chemotherapy in the management of NETs with an overview of past and present clinical trials, current treatment guidelines and future directions.
